Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People's Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer,… Read more
Laekna, Inc. (4U4) - Total Liabilities
Latest total liabilities as of June 2025: €200.55 Million EUR
Based on the latest financial reports, Laekna, Inc. (4U4) has total liabilities worth €200.55 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Laekna, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how Laekna, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Laekna, Inc. Competitors by Total Liabilities
The table below lists competitors of Laekna, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Baili Engineering Sci
SHG:603959
|
China | CN¥2.44 Billion |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
China | CN¥1.09 Billion |
|
Timbercreek Financial Corp
PINK:TBCRF
|
USA | $1.07 Billion |
|
Ichia Technologies Inc
TW:2402
|
Taiwan | NT$6.56 Billion |
|
Consolidated Communications
NASDAQ:CNSL
|
USA | $3.07 Billion |
|
Nederman Holding AB (publ)
PINK:NHOXF
|
USA | $4.27 Billion |
|
Actblue Co Ltd
SHE:300816
|
China | CN¥1.46 Billion |
|
Shanghai Newtouch Software Co. Ltd. A
SHG:688590
|
China | CN¥1.79 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Laekna, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laekna, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laekna, Inc. (2021–2024)
The table below shows the annual total liabilities of Laekna, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €155.25 Million | +20.97% |
| 2023-12-31 | €128.33 Million | -94.62% |
| 2022-12-31 | €2.38 Billion | +51.91% |
| 2021-12-31 | €1.57 Billion | -- |